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ABSTRACT
Increasing the upper age limit for recipients of hematopoietic stem cell transplantation (HCT) naturally has
also increased the age of the corresponding related donor population. Because aging is a risk factor formalignancies,
the risk of transferring preexisting malignant or premalignant hemopoietic clones in the process of HCTmight be
expected to increase as well. Anecdotal clinical cases of malignancies derived from donor cells in patients under-
going HCT have been published since 1971. In this article, we report 12 new cases that fit 2 different categories:
(1) cases in which clones with characteristics of lymphohemopoietic malignancies were transferred from the donors
to the recipients and (2) cases in which the malignant clone evolved from healthy donor cells once transplanted into
the recipient. Donors in the first group were significantly older than donors in the second group. Amore systematic
examination of the prevalence and biology of donor malignancies would merit study.
© 2006 American Society for Blood and Marrow Transplantation
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wNTRODUCTION
Neoplasias arising in cells of donor origin have
een described both after solid-organ transplantation
nd after hematopoietic cell transplantation (HCT).
he incidence of donor-related malignancies is ex-
remely low after the transplantation of solid organs
0.04%) [1]. In the realm of HCT, estimates of donor
alignancies have ranged from the anecdotal to as
igh as 5% [2]. Steady improvements in evaluating
onor-host chimerism by the molecular analysis of
hort tandem repeats (STR) and variable number of
andem repeats (VNTR), as well as sensitive ﬂow
ytometry, now allow for sensitive analysis of the do-
or or recipient origin of speciﬁc hematopoietic cell
opulations after HCT, thus setting the stage for
ncreased detection of donor malignancies.
In hematologic malignancies treated by HCT,
yeloablative (MA) conditioning regimens are rou- c
B&MTinely offered to patients up to 50 years old without
igniﬁcant comorbidities. Nonmyeloablative (NMA)
r reduced-intensity conditioning transplantations,
hich rely on the graft-versus-tumor effect to eradi-
ate the patient’s malignancy, have extended the age
imit for transplant recipients to 70 years of age
3,4]. Increased patient age is frequently accompanied
y increased donor age, at least with regard to sibling
onors. Because the incidence of most hematopoietic
alignancies increases with age, the likelihood of do-
or malignancies being transplanted into the HCT
ecipients should be increasing as well.
ATERIALS AND METHODS
In this article, we describe a series of cases in
hich hematopoietic malignancies appeared in donor
ells. All cases were identiﬁed by 1 of 2 methods: (1) a
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5alignant clone was detected on testing or (2) leuke-
ia was diagnosed either in the donor or the recipient.
hus, although this article is not a systematic review
f all patients who underwent transplantation in our
enters, it is a collective effort to gather all cases
iscovered during routine clinical care.
ESULTS
These cases are grouped by whether the malig-
ancy seemed to be actively transplanted from the
onor (Table 1) or seemed to have arisen from donor
ells after transplantation (Table 2).
econdary Malignancies Apparently Transplanted
rom the Donor
For this group of 5 males and 1 female, the median
ge was 53 years (range, 6-62 years; Table 1). The
riginal diagnoses were myeloﬁbrosis, myelodysplas-
ic syndrome (MDS), chronic lymphocytic leukemia
CLL), chronic myeloid leukemia (CML), acute lym-
hoblastic leukemia (ALL), and non-Hodgkin lym-
homa (NHL) in 1 patient each. Four of the patients
eceived MA and 2 received NMA HCTs. The stem
ell source was peripheral blood (PB) in 5 cases and
one marrow (BM) in 1 case.
The donor clones with a malignant immunophe-
otype included CLL in 3 cases and marginal zone
ymphoma, mantle cell lymphoma, and ALL in 1 case
ach. The methods used to conﬁrm that the aberrant
lones were of donor origin were VNTR analysis in 4
ases, analysis of STR in 1 case (performed in the
elected population with the malignant immunophe-
otype), and detection of the same clonal immuno-
lobulin heavy chain variable (v), diverse (D), and
oining (J) gene segments (immunoglobulin [Ig]H
DJ) rearrangement in the last case. The time interval
rom transplantation to the detection of the malignant
lone was relatively short (28-294 days) in 5 of these 6
ases. In the remaining case, the patient was tested for
he ﬁrst time 10 years after the transplantation. The
econdary malignant clones evolved to overt malignan-
ies in 2 of the 6 cases (follow-up, 3.5 months to 12
ears). The 2 cases of leukemia included ALL at 3
onths after HCT and CLL 12 years after transplanta-
ion.
The median age of the donors in this group was 53.5
ears (range, 36-70 years). Evidence of the malignant
lone was detected in 5 of the 6 donors. In 4 cases, the
lones detected had the same immunophenotype by ﬂow
ytometry that was found in their respective recipients,
nd in the last case, the donor and recipient presented
ith identical clonal IgH VDJ rearrangements. For the
ixth case, the donor was not available for testing. In 3 of
he 5 available donors, the clone evolved to clinical dis-
ase (1 ALL, 1 CLL, and 1 NHL).
12The malignant clone was detected ﬁrst in the
onor, rather than the patient, in 2 cases. In 1 case, the
onor had a diagnosis of ALL, and in the second case
he donor had a diagnosis of CLL (2 months and 2
ears after donating stem cells, respectively). The do-
or of the ﬁrst of these 2 cases developed ALL 2
onths after collection of stem cells. When the recip-
ent presented with a recurrence of her ALL, 130 days
fter the transplantation, the question arose whether
his represented a true relapse or whether the new
eukemia arose in the donor cells. To determine the
rigin of this second leukemic episode in the recipient,
TR analysis was performed on DNA obtained from
M of the recipient at the time of relapse, blood
amples from both sisters in remission, and buccal
wabs of the recipient, representing the pretransplan-
ation STR phenotype. The studies showed identical
roﬁles for 5 of the 5 informative loci tested for the
onor blood sample and the recipient BM at the time
f relapse. However, a different proﬁle was obtained
rom the DNA extracted from the buccal swab of the
ecipient, thus indicating the donor origin of the re-
ipient’s second leukemia.
In the second of these 2 cases, the donor was diag-
osed with CLL 2 years after the stem cell collection.
olymerase chain reaction analysis on an aliquot of the
onor’s BM stored at the time of the transplantation and
n a PB sample of the patient obtained 10 years after the
ransplantation revealed evidence of the same clonal IgH
DJ rearrangement present in the donor CLL. The
atient in this case developed clinical CLL 12 years after
he transplantation.
econdary Malignancies in Donor Cells
eveloping in the Host
The patients in this group included 5 males and 1
emale (Table 2). The median age was 36.5 years
range, 4-48 years), and the original diagnoses in-
luded CML in 3 and ALL, paroxysmal nocturnal
emoglobinuria/aplastic anemia, and renal cell carci-
oma in 1 patient each. Five of the patients received a
ull ablative transplant, and 1 patient received an
MA transplant. The stem cell source was PB in 2
ases and BM in 4 cases.
The secondary malignant clones were indicative of
DS in 5 cases [monosomy 7 in 2 cases and del(5q),
el(20q), and inv(11) in 1 case each] and acute myeloid
eukemia in 1 case. The methods used to conﬁrm that
he secondary malignant clone was of donor origin
ncluded karyotype analysis performed on the malig-
ant ﬂow-sorted cell populations in 3 of the cases in
hich patient and donor were of different sexes and
NTR analysis in the other 3 cases. In all 6 cases, the
ime from the transplantation to the detection of the
ew malignant clone was 1 year (median, 4 years;
ange, 1.25-26 years).The median donor age in this group was 41 years
Table 1. Secondary Donor-Derived Malignancies Transplanted from the Donor at the Time of Hematopoietic Stem Cell Infusion
Variable
Patient No.
1 2 3 4 5 6
Patient characteristics
Sex/age (y) Male/60 Male/62 Male/54 Female/6 Female/45 Male/52
Initial diagnosis MF MDS (RAEB) CLL CML ALL NHL
HCT type MA MA NMA MA MA NMA
Stem cell source PB PB PB BM PB PB
Conditioning BU, CY FLU, BU TBI TBI, CY TBI, CY TBI, FLU
Chronic GVHD Yes Yes Yes Yes No Yes
GVHD prophylaxis/
treatment
MTX, CSP/corticosteroids MTX, CSP/corticosteroids CSP, MMF/corticosteroids MTX, CSP/
corticosteroids,
CSP
MTX, CSP CSP, MMF/
corticosteroids
Secondary malignancy/time
from transplantation
MCL/55 d CLL/28 days MZL/294 d CLL/10 y ALL/130 d CLL/28 d
Detection technique Flow cytometry Flow cytometry Flow cytometry PCR clonality
analysis
Pathology and
flow cytometry
Flow cytometry
Donor origin confirmation Chimerism studies performed
by VNTR on BM CD5/
CD19-selected population
showed 100% donor origin
Chimerism studies performed
by VNTR on CD5/CD19-
selected population showed
100% donor origin
Chimerism studies performed
by VNTR on the
monoclonal CD20-
selected cell population
showed 100% donor origin
Leukemia-specific
IgH VDJ
rearrangement
detected in the
patient by PCR
Analysis of short
tandem repeats
Chimerism studies
performed by VNTR
on CD5/CD19-
selected population
showed 100% donor
origin
Progression to clinical
disease/patient’s LFU
No/3.5 mo No/2 y No/4.5 y Yes/12 y Yes/4 mo No/6 mo
Treatment None None None None Chemotherapy None
Cytogenetics at diagnosis
of secondary malignancy
NA 46, XY 46, XY NA 46, XX 46, XY
Donor characteristics
Donor’s match, related or
unrelated/age (y)
Matched related (brother)/56 Matched related (brother)/70 Matched related (brother)/57 Matched
unrelated
(male)/45
Matched related
(sister)/36
Mismatched (B allele,
C antigen) unrelated
(male)/51
Cytogenetics NA 46, XY NA NA NA NA
Neoplastic clone in donor Yes Yes Yes Yes Yes NA
Disease in donor No No Yes Yes Yes NA
Treatment in donor No No Yes (chemotherapy) Yes Yes (matched
related HCT)
NA
Donor’s LFU 2 mo NA 4.5 y 12 y 5.5 y NA
HCT indicates hematopoietic cell transplantation; GVHD, graft-versus-host disease; LFU, last follow-up; MF, myeloﬁbrosis; MDS, myelodysplastic syndrome; RAEB, refractory anemia with excess
blasts; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; VNTR, variable number of tandem repeats; ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin lymphoma; MA,
myeloablative; NMA, nonmyeloablative; PB, peripheral blood; BM, bone marrow; BU, busulfan; CY, cyclophosphamide; FLU, ﬂudarabine; TBI, total body irradiation; MTX, methotrexate; CSP,
cyclosporine; MMF, mycophenolate mofetil; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; PCR, polymerase chain reaction; NA, not available.
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Table 2. Secondary Donor-Derived Malignancies Developing in the Host
Variable
Patient No.
1 2 3 4 5 6
Patient characteristics
Sex/age (y) Male/40 Male/48 Female/33 Male/45 Male/11 Male/4
Initial diagnosis Renal cell Ca CML CML CML PNH/AA ALL
HCT type NMA MA MA MA MA MA
Stem cell source PB BM BM PB BM BM
Conditioning CY, ATG TBI, CY TBI, CY VP-16, TBI Procarbazine,
ATG, CY
TBI, CY
Chronic GVHD No Yes Yes Yes Yes Yes
GVHD prophylaxis/treatment CSP, MMF MTX, CSP/corticosteroids MTX, CSP/corticosteroids MTX, CSP MTX/ATG MTX, CSP
Secondary malignancy/time
from transplantation
AML/15 mo MDS (monos 7)/4 y MDS (monos 7)/4 y Del (20q)/3 y MDS (5q-)/26 y MDS inv (11)/4 y
Detection technique Pathology and flow
cytometry
Pathology and cytogenetics Pathology and cytogenetics Cytogenetics Pathology and
cytogenetics
Pathology and
cytogenetics
Donor origin confirmation VNTR analysis on AML
cells showed donor
origin
Chimerism studies by VNTR
showed 100% donor origin
hematopoiesis
Chimerism studies by VNTR
showed 100% donor origin
hematopoiesis
Cytogenetics Cytogenetics Cytogenetics
Progression to clinical
disease/patient’s LFU
Yes/1.75 y Yes/8 y Yes/9.5 y No/4 y Yes/26 y Yes/6 y
Treatment Autologous
transplantation
Pending matched unrelated
NMA HCT
Matched unrelated HCT None HCT HCT
Cytogenetics at diagnosis of
secondary malignancy
46, XY 45, XY, 7 45, XY, 7 46, XX, del(20q) 46, XX, del(5q) 46, XX, inv (11)
Donor characteristics
Donor’s match, related or
unrelated/age (y)
Matched related
(brother)/42
Matched unrelated
(male)/44
Mismatched (DR, DQ)
unrelated (female)/44
Matched related
(sister)/40
Matched related
(sister)/22
Mismatched (DR)
related (sister)/3
Cytogenetics NA NA NA 46, XX 46, XX 46, XX
Neoplastic clone in donor No NA NA No No No
Disease in donor No NA NA No No No
Treatment in donor No NA NA No No No
Donor’s LFU 21 mo NA NA 4 y 26 y 6 y
HCT indicates hematopoietic cell transplantation; GVHD, graft-versus-host disease; LFU, last follow-up; MDS, myelodysplastic syndrome; ALL, acute lymphoblastic leukemia; VNTR, variable number
of tandem repeats; MA, myeloablative; NMA, nonmyeloablative; PB, peripheral blood; BM, bone marrow; CY, cyclophosphamide; TBI, total body irradiation; MTX, methotrexate; CSP,
cyclosporine; MMF, mycophenolate mofetil; NA, not available; Ca, carcinoma; CML, chronic myeloid leukemia; PNH, paroxysmal nocturnal hemoglobinuria; AA, aplastic anemic; ATG,
antithymocyte globulin; VP-6, etoposide; AML, acute myeloid leukemia; monos, monosomy.
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Donor-Derived Hematologic Malignancies
Brange, 3-44 years). None of the 3 donors tested had
vidence of a hematopoietic malignant clone. We do
ot have information on the other 3 donors. All but 1
f the recipients developed overt disease and received
ggressive treatment with chemotherapy or a second
ransplantation.
In summary, secondary malignancies in our ﬁrst
roup tended to occur in the setting of older donors,
ere detected far sooner after transplantation, and
ere all of lymphoid lineage. In contrast, cases in the
econd group were associated with younger donors,
ad a longer time from transplantation to detection,
nd were exclusively myeloid. The donors in this ﬁrst
roup of cases were signiﬁcantly older than the donors
n the second group (P  .05; Student t test).
ISCUSSION
Between 1974 and 2004, more than 10 000 trans-
lantations have been performed at our institutions.
ere we report 12 new cases with clonal abnormalities
haracteristic of hematologic malignancies derived
rom donor cells after an HCT. These cases add to the
iterature of at least 49 cases of hematologic malig-
ancies in donor cells after HCT published since 1971
5-34]. Four previous articles have presented cases of
cute myeloid leukemia, MDS, T-cell lymphoma, and
ML [8,10,31,32] that were transplanted from the
onor into the patient. Here we present 6 additional
ases that ﬁt in this category: 3 CLLs, 1 marginal zone
ymphoma, 1 mantle cell lymphoma, and 1 ALL.
We divided this series of “secondary” hematologic
alignancies into 2 categories on the basis of the
ypothesis that they represent 2 different pathogenic
echanisms. The ﬁrst category includes patients in
hom the malignant clone was probably transferred at
he time of transplantation, concurrent with the infu-
ion of normal hemopoietic stem cells. The donor
alignancy in all cases was lymphoid. The second
ategory includes patients in whom the donor cells
eemed to have transformed into a malignancy after
ransfer into the recipient. Curiously, the donor ma-
ignancy in these cases was always myeloid. The me-
ian donor age in the ﬁrst group (53.5 years) was
igniﬁcantly older than the median donor age in the
econd group (41 years); this offers a suggestive asso-
iation of donor age and the development and transfer
f lymphoid disease. Studies have shown that B lym-
hocytes with abnormal CD5CD23 clonal immu-
ophenotypes may be present in healthy individuals
35], and their incidence may increase with age [36]. In
ddition, the bcl2-IgH translocation found in most
ollicular NHL cases has been found frequently in
ealthy individuals, with an increasing incidence with
rogressive age [37,38]. Although it is not clear that
hese age-related changes are premalignant, they
B&MTonetheless underscore that with age come genetic
hanges in the “normal” lymphohematopoietic system.
It is difﬁcult to estimate a true prevalence of
onor-derived malignancies in our transplant popula-
ion or to tell whether the incidence has increased
ver the years. The advent of sensitive techniques (eg,
ow cytometry) to detect malignant clones confounds
historical comparison. However, we speculate that
xtending the age limits for transplantation, with the
ssociated increase in donor age, has set the stage for
he increased appearance of age-related donor-derived
alignancies in transplant recipients. Given the rela-
ive rarity of these cases, however, it is difﬁcult to
dvocate wholesale screening of all donors for a “si-
ent” hematologic malignancy. A cost-effective ap-
roach might include more complete testing (ie, ﬂow
ytometry) of older donors with a family history of
ematologic malignancies or suspicious hematologic
est results in routine workup tests [39].
The detection of a donor malignancy in a patient
aises the question as to workup and consoling of the
onor. The small total number of cases reported thus
ar in the literature makes concrete advice difﬁcult.
rom our report and other recent publications [34], it
s clear that not all donors are destined to develop
isease themselves, particularly when the recipient
evelops a myeloid malignancy. Nonetheless, a careful
hysical and laboratory examination would seem in
rder for these donors.
Several mechanisms with respect to the transforma-
ion of donor-derived cells have been hypothesized: viral
r oncogene transfection from the host into the donor
ells, which is favored by the immunosuppressed status
hat follows transplantation; chronic antigenic stimula-
ion of donor cells once in the host; or premature aging
f the donor’s cells as a consequence of the replicative
ffort to repopulate the donor’s marrow [40]. Here we
resent evidence that the infusion of malignant cells into
CT recipients may also account for some of the cases
f malignancies in donor cells. A systematic research
tudy of the prevalence of occult secondary hematologic
alignancies in older donors would be useful to deter-
ine whether the hypothesized increased risk of donor
alignancies is real.
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